1)Fujita S, Mizusawa J, Kanemitsu Y, et al:Mesorectal excision with or without lateral lymph node dissection for clinical stage Ⅱ/Ⅲ lower rectal cancer(JCOG0212):a multicenter, randomized controlled, noninferiority trial. Ann Surg 266:201-207, 2017
2)大腸癌研究会(編):大腸癌取扱い規約,第9版.金原出版,2018,pp. 38-39
3)Saito S, Fujita S, Mizusawa J, et al:Male sexual dysfunction after rectal cancer surgery;results of a randomized trial comparing mesorectal excision with and without lateral lymph node dissection for patients with lower rectal cancer:Japan Clinical Oncology Group Study JCOG0212. Eur J Surg Oncol 42:1851-1858, 2016
4)Ito M, Kobayashi A, Fujita S, et al:Urinary dysfunction after rectal cancer surgery;results from a randomized trial comparing mesorectal excision with and without lateral lymph node dissection for clinical stage Ⅱ or Ⅲ lower rectal cancer(Japan Clinical Oncology Group Study, JCOG0212). Eur J Surg Oncol 44:463-468, 2018
5)小森康司,須田久雄,中井洋佑,他:血管合併切除を伴った巨大後腹膜腫瘍の手術の要点とトラブルシューティング.日臨外会誌80:485,2019
6)小森康司,木下敬史,大城泰平,他:側方リンパ節郭清後の直腸癌局所再発に対する手術の要点—特に高度癒着に対して腸骨動脈合併切除について.日消外会誌74:O4-O2,2019
7)小森康司,木下敬史,大城泰平,他:術前側方リンパ節転移陽性症例の治療方針と術式.外科82:717-723,2020
8)平井 孝:【大腸癌診療 最近の話題】直腸癌のD2,D3郭清の要点(解説/特集).コンセンサス癌治療7:76-79,2008